What KPV actually is

KPV is the C-terminal tripeptide (lysine-proline-valine) of α-melanocyte-stimulating hormone (α-MSH). It retains many of α-MSH’s anti-inflammatory effects without engaging the melanocortin pigmentation pathways.¹

Brzoska and colleagues have characterized KPV’s effects in models of contact dermatitis, inflammatory bowel disease, and arthritis. The tripeptide modulates NF-κB signaling, reduces pro-inflammatory cytokines, and shows particular efficacy at gut and skin mucosal surfaces.²

At Luxbae, KPV is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — NF-κB and cytokine modulation

Modulates NF-κB signaling, reduces TNF-α, IL-1β, and other pro-inflammatory cytokines at mucosal surfaces.²

What the research shows

Anti-inflammatory at mucosa. Documented effects at gut and skin mucosal surfaces.¹

IBD adjunct. Studied in colitis models with positive readouts.²

Wound healing. Inflammatory phase of wound healing modulated.

Side effects: Generally well-tolerated. Mild injection-site reactions or transient GI upset.

FDA note: Not FDA-approved. Prescribed under medical supervision as compounded protocol.

KPV FAQ

Will it darken my skin?
No — that’s α-MSH itself; KPV lacks the pigmentation effect.

Oral or injection?
Oral for GI focus; injection for systemic anti-inflammatory effect.

References

1. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocr Rev. 2008;29(5):581-602.
2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
3. Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-κB DNA binding. Biochem Pharmacol. 2001.